Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Has Generalized Anxiety For Paxil, Augmented Patent For Augmentin

Executive Summary

GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.

You may also be interested in...



GSK returns gemifloxacin rights

GlaxoSmithKline will return worldwide rights to quinolone antibiotic Factive (gemifloxacin) to development partner LG Chemicals Investments. Factive was deemed "not approvable" by FDA at the end of 2000 (1"The Pink Sheet" July 30, 2001, p. 20)...

GSK returns gemifloxacin rights

GlaxoSmithKline will return worldwide rights to quinolone antibiotic Factive (gemifloxacin) to development partner LG Chemicals Investments. Factive was deemed "not approvable" by FDA at the end of 2000 (1"The Pink Sheet" July 30, 2001, p. 20)...

PhRMA Anthrax Brochure Includes Off-Label Information Disclaimer

The Pharmaceutical Research & Manufacturers of America's anthrax educational brochure includes a disclaimer that the information has not been approved by FDA

Related Content

UsernamePublicRestriction

Register

PS038250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel